<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04696393</url>
  </required_header>
  <id_info>
    <org_study_id>AG348-C-021</org_study_id>
    <nct_id>NCT04696393</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult Participants</brief_title>
  <official_title>A Phase 1, Open-Label, Randomized, Two-Period, Crossover Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Agios Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Agios Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to characterize and compare the pharmacokinetic profiles&#xD;
      of mitapivat following a single dose administration of 100 mg mitapivat in two tablet&#xD;
      formulations (50 mg and 100 mg tablet strengths) in healthy adult participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 6, 2021</start_date>
  <completion_date type="Actual">March 19, 2021</completion_date>
  <primary_completion_date type="Actual">March 19, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC) of Mitapivat From Time 0 to the Last Quantifiable Concentration (AUC0-t)</measure>
    <time_frame>Pre-dose and multiple time points post-dose (up to 120 hours)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of Mitapivat From Time 0 Extrapolated to Infinity (AUC0-inf)</measure>
    <time_frame>Pre-dose and multiple time points post-dose (up to 120 hours)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Mitapivat</measure>
    <time_frame>Pre-dose and multiple time points post-dose (up to 120 hours)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Observed Plasma Concentration (Tmax) of Mitapivat</measure>
    <time_frame>Pre-dose and multiple time points post-dose (up to 120 hours)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Elimination Rate Constant (λZ) of Mitapivat</measure>
    <time_frame>Pre-dose and multiple time points post-dose (up to 120 hours)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Phase Half-life (t1/2) of Mitapivat</measure>
    <time_frame>Pre-dose and multiple time points post-dose (up to 120 hours)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Oral Clearance (CL/F) of Mitapivat</measure>
    <time_frame>Pre-dose and multiple time points post-dose (up to 120 hours)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vd/F) of Mitapivat</measure>
    <time_frame>Pre-dose and multiple time points post-dose (up to 120 hours)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 18 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Abnormal Clinical Laboratory Values</measure>
    <time_frame>Up to approximately 18 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Abnormal Findings for Vital Sign Parameters</measure>
    <time_frame>Up to approximately 18 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Abnormal Findings for 12-lead Electrocardiogram (ECG) Parameters</measure>
    <time_frame>Up to approximately 18 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Abnormal Physical Examination Findings</measure>
    <time_frame>Up to approximately 18 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Treatment Sequence 1: AB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment A (mitapivat 100 milligram [mg] tablet formulation, orally, under fasted conditions once on Day 1 of Period 1), followed by Treatment B (mitapivat 2 x 50 mg tablet formulation, orally, under fasted conditions once on Day 1 of Period 2). Each treatment period will be separated by a washout period of at least 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 1: BA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment B (mitapivat 2 x 50 mg tablet formulation, orally, under fasted conditions once on Day 1 of Period 1), followed by Treatment A (mitapivat 100 mg tablet formulation, orally, under fasted conditions once on Day 1 of Period 2). Each treatment period will be separated by a washout period of at least 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitapivat tablet</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>Treatment Sequence 1: AB</arm_group_label>
    <arm_group_label>Treatment Sequence 1: BA</arm_group_label>
    <other_name>AG-348</other_name>
    <other_name>AG-348 sulfate hydrate</other_name>
    <other_name>Mitapivat sulfate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has the ability to understand the requirements of the study and a willingness to&#xD;
             comply with all study procedures and has provided written informed consent before any&#xD;
             study-related procedures are conducted, and is willing to comply with all study&#xD;
             procedures for the duration of the study;&#xD;
&#xD;
          -  Has a body mass index (BMI) ≥18 and ≤32 kilograms per square meter (kg/m^2), at&#xD;
             screening;&#xD;
&#xD;
          -  Has a body weight ≥50 kg at screening;&#xD;
&#xD;
          -  Is medically healthy, with no clinically significant conditions or abnormalities, as&#xD;
             determined by the investigator or designee, through evaluation of medical history and&#xD;
             vital sign measurements, 12-lead ECG results, physical examination findings, and&#xD;
             clinical laboratory test results (congenital nonhemolytic hyperbilirubinemia [eg,&#xD;
             suspicion of Gilbert's syndrome based on total and direct bilirubin] is not&#xD;
             acceptable) at screening and check-in;&#xD;
&#xD;
          -  If female:&#xD;
&#xD;
               -  Is of childbearing potential and agrees to either abstain from sexual intercourse&#xD;
                  with a male partner or agrees to use a highly effective form of contraception,&#xD;
                  beginning at screening and continuing throughout the study and for 28 days after&#xD;
                  dosing or is postmenopausal (defined as 12 months or more continuously with no&#xD;
                  menses), or&#xD;
&#xD;
               -  Has a documented medical history of tubal ligation or hysterectomy;&#xD;
&#xD;
               -  The following are considered highly effective forms of contraception: hormonal&#xD;
                  oral contraceptives, injectables, and patches; intrauterine devices; double&#xD;
                  barrier methods (synthetic condom, diaphragm, or cervical cap used with&#xD;
                  spermicidal foam, cream, or gel); and male partner sterilization;&#xD;
&#xD;
          -  If male (even if vasectomized):&#xD;
&#xD;
               -  Agrees to either abstain from sexual intercourse with a female partner, or&#xD;
&#xD;
               -  Agrees to use a highly effective form of contraception (as defined above),&#xD;
                  starting at screening and continuing until 90 days after the final dose of&#xD;
                  mitapivat, and&#xD;
&#xD;
               -  Agrees to not donate sperm throughout the entirety of the study until 90 days&#xD;
                  after the final dose of mitapivat;&#xD;
&#xD;
          -  Agrees to abstain from any alcohol consumption, starting 72 hours prior to check-in&#xD;
             and continuing until the follow-up telephone call;&#xD;
&#xD;
          -  Agrees to refrain from marijuana- or cannabinol-containing products for 7 days prior&#xD;
             to screening until after the follow-up telephone call.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  At screening, presents with a condition or has a medical history that, in the opinion&#xD;
             of the investigator, may potentially interfere with study drug absorption,&#xD;
             distribution, metabolism, and/or excretion (eg, malabsorption [including due to cystic&#xD;
             fibrosis, lactose intolerance, celiac disease]);&#xD;
&#xD;
          -  At screening, presents with a surgical history that, in the opinion of the&#xD;
             investigator, may potentially interfere with study drug absorption, distribution,&#xD;
             metabolism, and/or excretion (eg, cholecystectomy). Participants who have undergone&#xD;
             abdominal surgery or any other major surgical procedure within 6 months prior to&#xD;
             screening, must not be enrolled;&#xD;
&#xD;
          -  Has a history or a presence of a primary malignancy, with the exception of a&#xD;
             malignancy that has been curatively treated and for which the participant has&#xD;
             displayed no evidence of disease within 12 months prior to screening;&#xD;
&#xD;
          -  Has a known history or presence of liver disease;&#xD;
&#xD;
          -  Is pregnant or breastfeeding;&#xD;
&#xD;
          -  Has a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus&#xD;
             antibody (HCVAb), or human immunodeficiency virus (HIV) types 1 or 2 antibodies at&#xD;
             screening;&#xD;
&#xD;
          -  Has liver test results including alanine aminotransferase (ALT), aspartate&#xD;
             aminotransferase (AST), alkaline phosphatase, and total bilirubin that are above the&#xD;
             upper limit of normal at screening or check-in (out-of-range test results may be&#xD;
             repeated once at screening and check-in, if needed);&#xD;
&#xD;
          -  Has estimated glomerular filtration rate (eGFR) &lt;60 milliliters per minute&#xD;
             (mL/min)/1.73 m^2 using the Chronic Kidney Disease Epidemiology Collaboration&#xD;
             (CKD-EPI) 2009 equation;&#xD;
&#xD;
          -  Has platelet, hemoglobin, or hematocrit test results that are below the lower limit of&#xD;
             normal at screening or check-in (out-of-range test results may be repeated once at&#xD;
             screening and check-in, if needed);&#xD;
&#xD;
          -  Has confirmed (ie, 2 consecutive measurements) systolic blood pressure (BP) &gt;150 or&#xD;
             &lt;90 millimeters of mercury (mmHg), diastolic blood pressure (BP) &gt;90 or &lt;50 mmHg, and&#xD;
             pulse rate &gt;100 or &lt;45 beats per minute (bpm) at screening and check-in;&#xD;
&#xD;
          -  Has clinically significant cardiac history or presence of ECG findings as determined&#xD;
             by the investigator at screening and check-in, including any of the following:&#xD;
&#xD;
               -  Abnormal sinus rhythm (heart rate [HR] lower than 45 bpm and higher than 100&#xD;
                  bpm);&#xD;
&#xD;
               -  Risk factors for torsades de pointes (eg, heart failure, cardiomyopathy, or&#xD;
                  family history of long QT syndrome);&#xD;
&#xD;
               -  Sick sinus syndrome, second- or third-degree atrioventricular block myocardial&#xD;
                  infarction, pulmonary congestion, cardiac arrhythmia, prolonged QT interval, or&#xD;
                  conduction abnormalities;&#xD;
&#xD;
               -  QT interval corrected for HR using Fridericia's formula (QTcF) &gt;450 milliseconds&#xD;
                  (msec) (male participants) or &gt;450 msec (female participants). In the event a&#xD;
                  QTcF value is outside of the reference range, it will be confirmed by 2 further&#xD;
                  repeat measurements, which will then be used to calculate a mean from the&#xD;
                  original value and the 2 repeat measurements;&#xD;
&#xD;
               -  QRS interval &gt;110 msec, confirmed by manual over read;&#xD;
&#xD;
               -  PR interval &lt;120 and &gt;220 msec;&#xD;
&#xD;
               -  Repeated or frequent syncope or vasovagal episodes;&#xD;
&#xD;
               -  Hypertension, angina, bradycardia (if assessed as clinically significant by the&#xD;
                  investigator), or severe peripheral arterial circulatory disorders;&#xD;
&#xD;
          -  Has clinically significant laboratory assessment findings, including hypokalemia,&#xD;
             hypercalcemia, or hypomagnesemia;&#xD;
&#xD;
          -  Has an active infection requiring systemic antimicrobial therapy at any time during&#xD;
             the screening period;&#xD;
&#xD;
          -  Has a positive urine drug screen (including cotinine) at screening or check-in;&#xD;
&#xD;
          -  Has a positive alcohol breath test result or positive urine drug screen at screening&#xD;
             or check-in;&#xD;
&#xD;
          -  Uses or intends to use any medications/products known to alter drug absorption,&#xD;
             metabolism, or elimination processes, including any over-the-counter medications or&#xD;
             herbal or nutritional supplements with the exception of vitamins, within 14 days (or 5&#xD;
             half-lives, whichever is longer) prior to check-in and until the follow-up telephone&#xD;
             call, unless deemed acceptable by the investigator (or designee). Note: After first&#xD;
             dosing, acetaminophen (up to 2 grams per 24 hours) may be administered at the&#xD;
             discretion of the investigator or designee;&#xD;
&#xD;
          -  Has used any prescription (excluding hormone replacement therapy and hormonal birth&#xD;
             control) medications, including systemic antimicrobial therapies, within 30 days (or 5&#xD;
             half-lives, whichever is longer) before the first dose of study drug or during the&#xD;
             study (ie, through the follow-up telephone call);&#xD;
&#xD;
          -  Is currently enrolled in or has participated in another clinical study to receive any&#xD;
             investigational or marketed product or placebo within 2 months (or 5 half-lives,&#xD;
             whichever is longer) prior to check-in;&#xD;
&#xD;
          -  Has donated blood or blood products or experienced blood loss of &gt;450 mL within 30&#xD;
             days prior to check-in;&#xD;
&#xD;
          -  Has received blood products within 2 months prior to check-in;&#xD;
&#xD;
          -  Has consumed caffeine- or xanthine-containing products within 24 hours prior to first&#xD;
             dose of study drug until after the follow-up telephone call;&#xD;
&#xD;
          -  Has consumed foods or beverages containing grapefruit or Seville oranges for 7 days&#xD;
             prior to the first dosing and is not willing to refrain from consumption of these&#xD;
             foods or beverages throughout the study;&#xD;
&#xD;
          -  Has ingested poppy seeds within 7 days prior to check-in until after the follow-up&#xD;
             telephone call;&#xD;
&#xD;
          -  Has consumed vegetables from the mustard green family (eg, kale, broccoli, watercress,&#xD;
             collard greens, kohlrabi, Brussel sprouts, and mustard greens), or charbroiled meats&#xD;
             within 7 days prior to first dose of study drug or throughout the study;&#xD;
&#xD;
          -  Has used nicotine-containing products (eg, snuff, nicotine patch, nicotine chewing&#xD;
             gum, mock cigarettes, vaporizers, or inhalers) within 6 months prior to screening,&#xD;
             based on participant self-reporting, and does not agree to abstain from use until the&#xD;
             follow-up telephone call;&#xD;
&#xD;
          -  Has a history of active alcoholism or drug/chemical abuse within 2 years prior to&#xD;
             check-in;&#xD;
&#xD;
          -  Average alcohol consumption of &gt;21 units per week for males and &gt;14 units for females&#xD;
             (1 unit is equal to approximately 1/2 pint [200 mL] of beer, or 1 small glass [100 mL]&#xD;
             of wine, or 1 measure [25 mL] of 40% spirits);&#xD;
&#xD;
          -  Has a history of relevant drug and/or food allergies (ie, allergy to study drug or&#xD;
             excipients [microcrystalline cellulose, croscarmellose sodium, sodium stearyl&#xD;
             fumarate, magnesium stearate, and mannitol]);&#xD;
&#xD;
          -  Has veins that are unsuitable for multiple venipunctures/cannulation, as assessed by&#xD;
             the investigator or designee at screening;&#xD;
&#xD;
          -  Is involved in strenuous activity or contact sports within 24 hours prior to check-in&#xD;
             or throughout the study;&#xD;
&#xD;
          -  Has any medical, hematological, psychological, or behavioral condition(s) or prior or&#xD;
             current therapy that, in the opinion of the investigator, may confer an unacceptable&#xD;
             risk to participating in the study and/or could confound the interpretation of the&#xD;
             study data;&#xD;
&#xD;
          -  Has a positive test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).&#xD;
             Note: Testing will be performed according to site procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PPD Development, LP</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 4, 2021</study_first_submitted>
  <study_first_submitted_qc>January 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

